Geoffrey Von Maltzahn
About Geoffrey Von Maltzahn
Geoffrey Von Maltzahn is a prominent entrepreneur and scientist, serving as the Founding CEO and Chairman of the Board at Cobalt Biomedicine, Inc., and holding various leadership roles in multiple biotechnology companies. He has a strong academic background in biomedical engineering and chemical engineering from the Massachusetts Institute of Technology and has been recognized for his significant contributions to the field through numerous awards and patents.
Work at Tessera Therapeutics
Geoffrey Von Maltzahn serves as the Founding CEO and Chairman of the Board at Tessera Therapeutics, a position he has held since 2018. Under his leadership, the company focuses on advancing genetic medicines through its innovative platform. His role involves strategic oversight and guiding the company's vision in the biotechnology sector, particularly in the development of therapies that leverage genetic technologies.
Current Roles in Biotechnology
In addition to his position at Tessera Therapeutics, Geoffrey Von Maltzahn holds several other significant roles in the biotechnology field. He is the Founding CEO of Quotient Therapeutics since 2022 and has been the Founding CEO of Cobalt Biomedicine, Inc. since 2016. He also co-founded Sana Biotechnology, Inc. and serves as a Board Member. His involvement in multiple organizations highlights his commitment to advancing biomedicine and innovation.
Education and Expertise
Geoffrey Von Maltzahn has a robust educational background in engineering and biomedical sciences. He earned a PhD in Biomedical Engineering and Medical Physics from the Massachusetts Institute of Technology (MIT) from 2005 to 2010. Prior to that, he completed a Master of Science in Bioengineering at the University of California, San Diego, and obtained a Bachelor of Science in Chemical Engineering from MIT. This extensive education underpins his expertise in the biotechnology sector.
Achievements and Recognitions
Geoffrey Von Maltzahn has received numerous accolades for his contributions to science and innovation. He has been recognized by the World Economic Forum, Forbes, and other prominent organizations for his inventions. He received the Lemelson-MIT Student Prize for his work in invention and innovation and has been featured in lists such as Business Insider's 30 under 40 young leaders. His inventions have been acknowledged as significant breakthroughs in science.
Contributions to Scientific Research
Geoffrey Von Maltzahn has made substantial contributions to scientific research, co-authoring 20 peer-reviewed publications and holding over 200 patents and patent applications. He played a pivotal role in the discovery of SER-109 during his time as CTO of Seres Therapeutics. His work has been recognized for its impact on the field of biotechnology and has been highlighted as key advancements in scientific research.